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ABSTRACT 
Background & Aims: Lynch syndrome is caused by variants in DNA mismatch repair (MMR) genes 
and associated with an increased risk of colorectal cancer (CRC). In patients with Lynch syndrome, 
CRCs can develop via different pathways. We studied associations between Lynch syndrome-
associated variants in MMR genes and risks of adenoma and CRC and somatic mutations in APC 
and CTNNB1 in tumors in an international cohort of patients. 
 
Methods: We combined clinical and molecular data from 3 studies. We obtained clinical data from 
2747 patients with Lynch syndrome associated with variants in MLH1, MSH2, or MSH6 from 
Germany, the Netherlands, and Finland who received at least 2 surveillance colonoscopies and 
were followed for a median time of 7.8 years for development of adenomas or CRC. We 
performed DNA sequence analyses of 48 colorectal tumors (from 16 patients with mutations in 
MLH1, 29 patients with mutations in MSH2, and 3 with mutations in MSH6) for somatic mutations 
in APC and CTNNB1. 
 
Results: Risk of advanced adenoma in 10 y was 17.8% in patients with pathogenic variants in 
MSH2 vs 7.7% in MLH1 (P<.001). Higher proportions of patients with pathogenic variants in MLH1 
or MSH2 developed CRC in 10 y (11.3% and 11.4%) than patients with pathogenic variants in MSH6 
(4.7%) (P=.001 and P=.003 for MLH1 and MSH2 vs MSH6, respectively). Somatic mutations in APC 
were found in 75% of tumors from patients with pathogenic variants in MSH2 vs 11% in MLH1 
(P=.015). Somatic mutations in CTNNB1 were found in 50% of tumors from patients with 
pathogenic variants in MLH1 vs 7% in MSH2 (P=.002). None of the 3 tumors with pathogenic 
variants in MSH6 had a mutation in CTNNB1, but all had mutations in APC. 
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Conclusions: In an analysis of clinical and DNA sequence data from patients with Lynch syndrome 
from 3 countries, we associated pathogenic variants in MMR genes with risk of adenoma and CRC, 
and somatic mutations in APC and CTNNB1 in colorectal tumors. If these findings are confirmed, 
surveillance guidelines might be adjusted based on MMR gene variants. 
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INTRODUCTION 
Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, 
accounting for approximately 3% of all cases of CRC.
1
 LS is an autosomal dominant inherited 
disorder caused by pathogenic germline variants in mismatch repair (MMR) genes, including 
MLH1, MSH2 (EPCAM), MSH6 and PMS2. Carriers of such gene defects are at high risk of 
developing primarily CRC and endometrial cancer, but also other malignancies.
2
 The main features 
of LS include an early age of cancer onset, a high risk of developing multiple cancers, and 
microsatellite instability and loss of MMR expression in the tumors.
3
 The risk of developing a 
specific cancer type in LS depends on the underlying germline MMR defect.
4-6
 
Carriers of pathogenic MMR gene variants show an increased frequency of adenoma development 
compared to non-carriers undergoing intensive colonoscopic surveillance.
7
 In addition, a Finnish 
study demonstrated that colonoscopy with polypectomy reduces CRC incidence and CRC mortality 
by >50%.
8
 Together these observations confirmed the role of adenomas in the development of 
CRC in LS and constitute the basis for colonoscopic surveillance programs. 
4, 9
 
Nevertheless, a substantial number of carriers develop CRC despite colonoscopic surveillance.
10-12
 
Recent publications report risks of CRC of up to 46% in patients under surveillance, with much 
higher risks found for MLH1 and MSH2 carriers (43-46%) than for MSH6 (15%) and PMS2 carriers 
(0%).
13
 Another recent prospective study evaluated the risk of incident CRC in a large series of 
MLH1, MSH2, or MSH6 carriers from Germany, Finland and the Netherlands.
14
 Despite intensive 
surveillance, 4-18% of the carriers developed CRC after 10 years of follow-up, independently of the 
screening interval.  
In 2016, Ahadova et al. hypothesized that LS-CRC might develop through a pathway characterized 
by a lack of adenomatous tissue and by immediate invasive growth under the mucosal surface.
15
 
The authors suggested that these LS-CRCs may emerge from MMR-deficient crypt foci that grow 
under the mucosal surface and cannot be detected by colonoscopy at a pre-invasive stage, 
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potentially explaining CRC development despite colonoscopic surveillance and polypectomies.
16
 It 
was subsequently demonstrated that LS-CRCs are heterogeneous and can develop via different 
molecular pathways with distinct initiating events: whereas some LS-CRCs develop from MMR-
proficient adenomas, the majority develop from MMR-deficient lesions, either via an 
adenomatous phase or in the absence of a detectable  precursor lesion.
17
 Nonetheless, the impact 
of certain MMR gene mutations on the development of particular CRC subtypes remains unclear. 
The development of CRC despite surveillance is an important problem in the clinical management 
of LS and deserves closer examination to clarify the underlying mechanisms. A better 
understanding of carcinogenesis in each specific group of pathogenic MMR variant carriers will 
have important consequences for decision-making on appropriate surveillance intervals. 
The purpose of this study was to assess possible differences in the pathways of CRC development 
between MLH1, MSH2 and MSH6 carriers. Our specific aims were (1) to compare risks for 
(advanced) adenoma and CRC, and (2) to compare the frequencies of CTNNB1 and APC mutations 
in CRCs between MLH1, MSH2 and MSH6 carriers.  
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METHODS 
Study population 
This report combines clinical and molecular data obtained in the course of three earlier studies. 
The clinical part is based on data from a prospective cohort study conducted to compare CRC 
incidence and stage in LS patients from three different countries (Germany, the Netherlands, 
Finland) recommending different colonoscopy intervals.
14
 The study population has been 
described in detail elsewhere.
14
 Briefly, the cohort consisted of 2,747 LS patients included in the LS 
registries of Germany, the Netherlands, and Finland. In all three registries, LS patients were 
followed prospectively within a framework of intensive colonoscopic surveillance programs. 
Written informed consent was obtained from all LS patients enrolled in the registries and who 
participated in prospective surveillance studies. Patients were eligible for the present analysis if 
they i) were carriers of a pathogenic germline variant in either the MLH1, MSH2 or MSH6 gene, 
and ii) had completed at least two surveillance colonoscopies after registry inclusion. For each 
colonoscopy, age at examination and worst finding (normal, adenoma, advanced adenoma, CRC) 
were noted, and for each CRC the age at diagnosis was recorded. An advanced adenoma was 
defined by a size of >1cm or the presence of either villous histology or high-grade dysplasia. 
In the present analysis, we used this study population to compare the cumulative incidences of 
(advanced) adenomas and CRC between the MLH1, MSH2, and MSH6 carriers. 
 
Molecular analysis and histology assessment 
Separately from the clinical part, the molecular part of the present report represents a re-analysis 
of data from two studies reported previously.
15, 17
 Briefly, formalin-fixed paraffin-embedded (FFPE) 
tissue blocks from LS-CRCs were collected within the Department of Applied Tumor Biology, 
Institute of Pathology, University Hospital Heidelberg. Tumor tissue was microdissected from FFPE 
tissue sections and DNA was isolated for the downstream analyses. Histopathology review 
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revealed a tumor cell content of more than 50% in all studied samples. Mutational analysis was 
performed either by targeted Sanger sequencing (for determination of CTNNB1 mutation status) 
or by Illumina panel sequencing of mutation HotSpot regions in 30 genes, including CTNNB1 and 
APC.
18
 The data were analyzed by Sequencing Analysis Software and Ion Torrent Suite Software, 
respectively. Only variants with an allele frequency >5% and minimum coverage >100 reads were 
taken into account. For the purposes of the present study, molecular data obtained from CRCs 
were sorted depending on the underlying MMR defect. All patients provided informed, written 
consent and the study was approved by the relevant Institutional Ethics Committee. 
 
Statistical analysis 
In the clinical cohort, prospective observation started with the first colonoscopy conducted after 
enrollment in the LS register (index colonoscopy) and ended with the last colonoscopy or the 
occurrence of a primary CRC diagnosis. CRCs detected at the index colonoscopy were defined as 
prevalent CRCs. All other CRCs detected during prospective observation were defined as incident 
cancers. The occurrence of incident extra-colonic tumors was ignored if surveillance colonoscopies 
were continued after such an event. Time to incident (advanced) adenoma or CRC was analyzed 
using the Kaplan-Meier method, with time zero at the index colonoscopy and group comparisons 
made using the log-rank test. Additionally, we performed multivariate Cox regression analyses 
adjusting for age at index colonoscopy and country as confounders, the latter reflecting the 
differences in colonoscopy intervals and the differences in the proportions of patients with prior 
CRC. Comparisons of categorical data between groups were performed using the chi-square test, 
or Fisher's exact test where appropriate. P values below 0.05 were considered statistically 
significant. All analyses were carried out using IBM SPSS Statistics for Windows, Version 24.0 (IBM 
Corp., Armonk, NY, USA). 
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RESULTS 
Risk of (advanced) adenomas and CRC  
The clinical cohort comprised 2,747 LS patients in total (1,027 from Germany, 806 from the 
Netherlands, and 914 from Finland). Basic patient characteristics can be found in Table 1. A total 
of 1,038 patients (38%) already had a prior CRC before the index colonoscopy. Due to the presence 
of two MLH1 founder mutations in the Finnish population, the proportion of MLH1 carriers was 
higher in Finland (79%) compared to Germany (39%) and the Netherlands (35%). Patients had a 
median of five consecutive colonoscopies (16,327 colonoscopies in total). The median per-patient 
observation time was 7.8 years (interquartile range 4.2 to 12.0). The cumulative prospective 
observation time amounted to 23,309 person-years in total. At the index colonoscopy, the 
frequency of prevalent adenomas was 10.2% and the frequency of prevalent CRC was 2.3%. 
Figure 1 shows the comparison of the cumulative risk of incident adenoma between MLH1, MSH2 
and MSH6 carriers. Ten years after the index colonoscopy, the highest risk was observed in MSH2 
carriers (44.2%, 95%CI 40.0-48.4%), followed by MSH6 carriers (38.4%, 95%CI 30.8-45.9%), and 
was lowest in MLH1 carriers (32.2%, 95%CI 29.2-35.2%). The differences in risk between MLH1 and 
MSH2 carriers (p<0.001) and between MLH1 and MSH6 carriers (p=0.029) were statistically 
significant, but not between MSH2 and MSH6 carriers (p=0.400). Figure 2 shows the comparison of 
the cumulative risk of incident advanced adenoma between the three groups. Ten years after the 
index colonoscopy, the risk of advanced adenoma was similar for MLH1 and MSH6 carriers (7.7%, 
95%CI 6.0-9.4% and 9.4%, 95%CI 5.4-13.4%, respectively, p=0.543), but both had a significantly 
(p<0.001 and p=0.010, respectively) lower risk than MSH2 carriers (17.8%, 95%CI 14.6-21.0%). 
Figure 3 shows the cumulative risks for incident CRC. Ten-year CRC risks were almost identical for 
MLH1 and MSH2 carriers (11.3%, 95%CI 9.4-13.2% and 11.4%, 95%CI 8.9-14.0%, respectively, 
p=0.468). In contrast, CRC risk in MSH6 carriers was significantly lower (4.7%, 95%CI 1.8-7.7%) 
compared to MLH1 (p=0.001) and MSH2 (p=0.003) carriers. Multivariate Cox regression analyses 
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adjusting for age at index colonoscopy and country revealed similar results regarding significant 
group differences except for adenoma risk between MLH1 and MSH6 carriers, which was not 
significant (p-adjusted=0.265) compared to the unadjusted analysis. 
 
Molecular features of LS-CRC 
Molecular analysis was performed on CRCs from 16 MLH1, 29 MSH2, and 3 MSH6 carriers. Allele 
frequencies of the observed somatic mutations ranged between 21% and 73%. The results are 
summarized in Table 2. Of the 16 MLH1-associated CRCs, eight displayed somatic CTNNB1 
mutations (50%, 95%CI: 28.0-72.0%), whereas only two somatic CTNNB1 mutations were detected 
in the 29 MSH2-associated CRCs (7%, 95%CI: 0.9-23.0%), demonstrating a significantly higher 
proportion of somatic CTNNB1 mutations in MLH1- compared to MSH2-associated CRCs (p=0.002). 
In contrast, somatic APC mutations were detected in only one of nine MLH1-associated CRCs (11%, 
95%CI: 0-45.7%), whereas MSH2-associated CRCs carried somatic APC mutations in six out of eight 
analyzed CRCs (75%, 95% CI: 40.1-93.7%, p=0.015). None of the three MSH6-associated CRCs 
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DISCUSSION 
Previous studies in LS have shown that up to 1 in 5 patients develop CRC despite intensive 
colonoscopic surveillance.
8, 10-12, 14
 MLH1 and MSH2 carriers under surveillance are at high risk of 
CRC, whereas MSH6 carriers have a much lower risk, and PMS2 carriers may even have zero CRC 
risk under surveillance.
13
 The main goal of the present study was to evaluate whether the 
molecular pathways of carcinogenesis are different between MLH1, MSH2 and MSH6 carriers and 
therefore explain the observed differences in adenoma and CRC risk and the effectiveness of 
screening programs. 
The prospective clinical data of our study demonstrates that the risk of adenomas is significantly 
greater in MSH2 and MSH6 carriers compared to MLH1 carriers, and that the risk of advanced 
adenomas is higher in MSH2 carriers compared to both MLH1 and MSH6 carriers. However, 
incident CRC was more frequently observed in MLH1 and MSH2 carriers than in MSH6 carriers. 
This is in contrast to a recently published single center study involving 242 MLH1, MSH2 and MSH6 
carriers over 1739 years of follow-up, which could not detect significant differences in (advanced) 
adenoma incidence between MMR genes, probably due to the low sample size.
19
  
Our study also demonstrates molecular differences in the carcinogenesis between MLH1- and 
MSH2-associated LS-CRCs. Whereas MSH2-associated CRCs presented with a higher frequency of 
somatic APC mutations compared to MLH1-associated CRCs, a significantly higher frequency of 




Interestingly, incident CRC risk in MLH1 carriers was as high as in MSH2 carriers, but MLH1 carriers 
presented with a substantially lower (advanced) adenoma incidence than MSH2 carriers. 
Moreover, the cumulative risk for advanced adenoma in MSH2 carriers was higher than the CRC 
risk, which agrees with the notion that not all adenomas develop into cancer. In MLH1 carriers, 
however, the risk for advanced adenoma was lower than the incident cancer risk. Assuming similar 
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progression rates for MLH1- and MSH2-associated advanced adenomas into CRC, this observation 
might suggests different pathways of CRC development in MLH1 versus MSH2 carriers. Seen in the 
light of the enhanced CRC risk in both MLH1 and MSH2 carriers and their molecular characteristics, 
it is conceivable that somatic CTNNB1 and APC mutations, in combination with MMR deficiency, 
may both contribute to tumor progression. Whereas MSH2-associated cancers may have an 
accelerated adenoma-carcinoma sequence with somatic APC mutations often following MMR 
deficiency, a substantial proportion of MLH1-associated cancers may progress without prior polyp 
formation through an immediate invasive pathway, presumably arising from MMR-deficient crypts 
due to acquired somatic CTNNB1 mutations. 
The higher frequency of somatic APC mutations in CRCs of MSH2 vs. MLH1 carriers is in line with 
the observed higher incidence of (advanced) adenomas in MSH2 vs. MLH1 carriers, as APC 
mutations are often associated with adenoma development in the colonic epithelium.
22
  
Both MSH2- and MSH6-associated CRCs presented with a high proportion of somatic APC 
mutations and a low proportion of somatic CTNNB1 mutations. While this finding should be 
validated in a larger cohort in the case of MSH6-associated CRCs, this outcome is intriguing since 
MSH6 carriers show a lower risk of advanced adenoma development compared to MSH2 carriers. 
One explanation for this observation could be an incomplete MMR deficiency caused by MSH6 
loss, with predominantly mononucleotide repeats affected, which potentially lowers the likelihood 
of driver mutations secondary to MMR deficiency.
23
 This is further corroborated by the 
observation of MSH6-deficient cancers that lack MSI
24
 and possibly indirectly by a lower 
proportion of MMR-deficient adenomas (approximately 27%) in MSH6 carriers compared to MSH2 
or MLH1 carriers (75-80%), as demonstrated previously.
17, 20, 25, 26
  
In view of the low frequency of MMR-deficient adenomas in MSH6, it is conceivable that MMR-
deficient crypt foci are either less common or less likely to progress in MSH6 carriers. Progression 
according to the classic adenoma-carcinoma sequence, with MMR deficiency occurring after 
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adenoma development, could therefore be the more frequent pathway of carcinogenesis in this 
group of carriers. This hypothesis is supported by the observation of low grade adenomas 
presenting with an MSS phenotype in MSH6 carriers, in contrast to MLH1 carriers.
27, 28
 As a 
consequence, surveillance colonoscopy with polypectomy might be more effective in MSH6 
carriers, as described in a recent study.
13
 
A similar hypothesis might explain the high efficacy of colonoscopic screening in PMS2 carriers. 
Adenomas in these patients are usually MMR-proficient and PMS2-associated CRCs do not 
commonly present with somatic CTNNB1 mutations.
21
 Thus, the lower CRC risks observed in MSH6 
and PMS2 carriers under surveillance might be explained by inherently lower risks of CRC 
development in these carriers, but may also be partly due to a different pathogenesis and thereby 
more effective prevention by polypectomy.  
The current study had several strengths, as well as some limitations. A major strength of the 
clinical part was the large prospective cohort with long duration of follow-up. A limitation was the 
low number of CRCs from MSH6 carriers available for molecular studies, which does not allow 
drawing definitive conclusions. It is also important to note that the molecular data were not 
obtained from the CRCs of the clinical cohort, but from separate CRC samples. Since the selection 
of these samples did not differ from the selection of patients for the clinical part of the study, this 
should not have influenced the results of our study in a major way. However, prospective 
validation in a larger number of cancers is warranted. 
What are the implications of our findings for clinical practice? Our results suggest that the high 
CRC risk in MLH1 and MSH2 carriers under surveillance might be largely attributed to the 
molecular characteristics of the CRCs, possibly contributing to a fast adenoma-carcinoma 
sequence or initial submucosal growth in the absence of adenomatous tissue. The development of 
CRC despite intensive surveillance colonoscopy in these groups of carriers should therefore be 
considered as part of the phenotype. Fortunately, most CRCs detected by screening are local, 
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without metastatic disease, and almost all patients have a favorable outcome.
6, 29
 These 
considerations should be discussed with the patients, and it should be emphasized that detection 
of a CRC during intensive colonoscopic surveillance is not surprising and does not necessarily 
indicate a failure of the surveillance program. In contrast, colonoscopy and polypectomy are 
effective in almost all MSH6 carriers, as also reported for PMS2 carriers.
6
  
In conclusion, this is the first study to compare clinical and molecular findings between carriers of 
alterations in the MMR genes MLH1, MSH2 and MSH6. Our results suggest that growth 
characteristics and accumulation of certain molecular alterations may explain the high CRC risk in 
both MLH1 and MSH2 carriers. Despite similar CRC risks there were remarkable differences in 
CTNNB1 and APC mutation frequencies between MLH1 and MSH2 carriers. The previously 
reported low frequency of MMR deficiency in MSH6-associated adenomas, in combination with 
the low frequency of CTNNB1 mutations and the higher frequency of APC mutations, suggests that 
an MMR-deficient polypous pathway in MSH6 carriers typically arises after the development of 
adenomas. If these findings are confirmed in future studies, surveillance guidelines might be 
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FIGURES 
Figure 1. Cumulative incidence of adenoma by affected gene (MLH1, MSH2, MSH6) 
Figure 2. Cumulative incidence of advanced adenoma by affected gene (MLH1, MSH2, MSH6) 





Table 1: Clinical characteristics of patients in the clinical cohort 
 MLH1 MSH2 MSH6 Total 
 n = 1407 n = 986 n = 354 n = 2747 



































CRC before index colonoscopy, no (%) 526 (37.4) 405 (41.1) 107 (30.2) 1038 (37.8) 
Age at index colonoscopy, mean (±SD) 









Number of colonoscopies 














Observation time, years 














Incident CRC, no of patients / CRC 167 / 169 93 / 97 12 / 13 272 / 279 




Table 2. Presence of somatic mutations in CTNNB1 and APC in tumors of MLH1, MSH2, and 
MSH6 carriers 
 MLH1 MSH2 MSH6 
 n = 16 n = 29 n = 3 
Age at diagnosis, median 46 45 55 
CTNNB1 mutated 8 of 16 (50%) 2 of 29 (7%) 0 of 3 (0%) 
APC mutated 1 of 9 (11%) 6 of 8 (75%) 3 of 3 (100%) 





What you need to know: 
BACKGROUND AND CONTEXT: Lynch syndrome is caused by variants in DNA mismatch repair 
(MMR) genes and is associated with an increased risk of colorectal cancer (CRC). Variants in 
MMR genes are likely to have different effects on CRC and adenoma risk. 
 
NEW FINDINGS: In an analysis of adenomas and colorectal tumors from patients with Lynch 
syndrome from 3 countries, we associated pathogenic variants in MMR genes with risk of 
adenoma and CRC, and with somatic mutations in APC and CTNNB1. 
 
LIMITATIONS: We analyzed DNA sequences of 48 tumor samples. Larger studies of CRC 
development, and features of tumors, are needed in patients with Lynch syndrome. 
 
IMPACT: Surveillance guidelines for patients with Lynch syndrome might need to be adjusted 
based on MMR gene variants. 
 
Lay Summary: Lynch syndrome is caused by alterations in a specific group of genes. Patients 
with different types of genetic alterations develop adenomas and CRC at different rates, and 
tumors have specific genetic features.  
 
 
